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Abstract: Advances in lab-on-a-chip systems have strong potential for multiplexed 
detection of a wide range of analytes with reduced sample and reagent volume; lower costs 
and shorter analysis times. The completion of high-fidelity multiplexed and multiclass 
assays remains a challenge for the medical microdevice field; as it struggles to achieve and 
expand upon at the point-of-care the quality of results that are achieved now routinely in 
remote laboratory settings. This review article serves to explore for the first time the key 
intersection of multiplexed bead-based detection systems with integrated microfluidic 
structures alongside porous capture elements together with biomarker validation studies. 
These strategically important elements are evaluated here in the context of platform 
generation as suitable for near-patient testing. Essential issues related to the scalability of 
these modular sensor ensembles are explored as are attempts to move such multiplexed and 
multiclass platforms into large-scale clinical trials. Recent efforts in these bead sensors 
have shown advantages over planar microarrays in terms of their capacity to generate 
multiplexed test results with shorter analysis times. Through high surface-to-volume ratios 
and encoding capabilities; porous bead-based ensembles; when combined with 
microfluidic elements; allow for high-throughput testing for enzymatic assays; general 
chemistries; protein; antibody and oligonucleotide applications.  
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1. Introduction 
Diagnostic tools are critical to the delivery of effective healthcare treatment, yet current in vitro 
diagnostic (IVD) devices to date have been shown to be incapable of keeping pace with the rapidly 
increasing information content related to disease diagnosis and progression generated with advanced 
“omics” methods such as genomics, proteomics, metabolomics and glycomics [1,2]. Here, despite the 
thousands of biomarker discovery papers published, only 1.5 protein biomarkers per year on average 
have received US FDA approval during the past 15 years [3–6]. Unfortunately, most modern clinical 
analyzers are dedicated to single classes of analytes and are burdened by bulky, expensive,  
laboratory-confined instrumentation preventing broad access to these assays at the point-of-care (POC). 
The movement of new technologies to POC settings and the use of noninvasive sampling modalities 
have important implication in terms of improvement in the efficiency of the delivery of healthcare. 
Unfortunately, to date POC devices suffer in two major respects relative to their remote laboratory 
counterparts. First, in general the POC devices are more expensive and, second, these portable systems 
more often than not, yield performance inferior to that derived from traditional laboratory settings [7,8]. 
Furthermore, large sample volume requirements and lack of standard instrumentation that is responsive 
to a broad range of analytes complicate clinical validation studies that need to follow the initial 
discoveries and proof of principle phases. 
Traditional approaches to clinical analysis involve a well-appointed centralized laboratory, three 
degrees of separation from the patient. This hierarchy introduces a number of critical junctures in 
which errors may be introduced and delays incurred. To simplify and offer assay results immediately, 
research into devices that give results at the POC, specifically bedside, ambulance or remote location, 
currently flourishes—a situation advantageous to both patients and healthcare providers [9–13]. POC 
diagnostic systems have been extensively reviewed in recent years, from both the points of view of 
usage [14–16] and fabrication [17–19]. The ability to process large amounts of information at the  
point-of-need is common in the field of electronics, yet the ability to similarly process complex 
molecular disease signatures has not yet been fully demonstrated [7]. The marriage of microelectronics 
and IVD areas provides huge opportunities to healthcare industries seeking affordable and accessible 
diagnostic infrastructures [7,20]. 
In the past few decades, significant advances in medical microdevice technologies have afforded 
new sensor ensembles capable of multiplexed detection of a wide range of analytes [21–23], including 
diagnostic targets, such as disease-specific proteins [15], metabolites and other small molecules [24], 
nucleic acids [25–27], bacteria and bacterial spores [28–34], and human cells [19,35,36]. Diagnostic 
devices for limited-resource settings, including the developing world, have seen significant 
development efforts recently as this area requires new affordable technologies that can work outside of 
the traditional laboratory settings [19,36–41].  
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Through the miniaturization of macro-components, micro total analysis system (μTAS) and lab on a 
chip (LOC) devices have ushered in a new generation of high-throughput testing modalities that 
promise new options for biomarker measurements [7,42–44]. For example, Quake’s work has 
advanced the “large-scale integration” of microfluidics, analogous to the electronics field [20]. Mirkin, 
Heath and Wang used nanowires, precious metal nanoparticles, and magnetic techniques, respectively, 
to measure diverse sample types and create a variety of assembly types [13,45,46], while Sia has 
introduced more integrated approaches via microelectromechanical systems [47]. Singh has continued 
to increase integration through the use of chip-based separation and quantitation [48]. Both Singh and 
Ligler have extended their integrated approaches into the rapid, multiplexed detection of toxins and 
other biothreats [49]. Work by Madou and others have resulted in the LabCD, which eliminates 
traditional active mechanical valves and pumps by using centrifugal and centripetal force to perform 
fluid movement and control [50]. Walt’s work with electronic noses uses arrays of optical fibers as the 
underlying infrastructure for biological sensing systems [51]. Finally, researchers in the Toner group 
have explored a number of novel methods for the isolation and enumeration of lymphocytes, 
erythrocytes, and circulating tumor cells [52,53]. 
There now is a strong potential to leverage these medical microdevice discoveries for a broad 
impact in diagnostics for IVD and global heath applications using such chip-based approaches. 
Unfortunately, to date very few complete workable POC clinical devices have emerged despite 
tremendous progress in LOC, microfabrication, microfluidics, and related areas [43,54]. Indeed, while 
the core of typical LOC systems is substantially smaller than that of the bench-top counterparts, most 
systems still rely on a network of macroscopic laboratory-based infrastructure for sample processing, 
sample introduction, analyte detection, data processing, and reagent handling, thus limiting their utility 
for POC applications [7]. 
In addition to key work in the LOC area, which includes on-chip sample processing, significant 
progress has also been made recently in the area of protein, antibody and oligonucleotide planar 
microarray technologies with off-chip (i.e., lab confined) sample processing. The emergence of  
high-density planar microarrays has enabled parallelized testing for clinical testing and validation. 
With modest sample volume requirements, these microarrays have afforded multiplexed testing of 
hundreds to thousands of analytes simultaneously for both proteomic and genomic applications [55–59]. 
Unfortunately, the cumbersome and time-consuming processing steps, as well as the large expense of 
the microarray disposable elements, have limited their utility to sophisticated research settings. Thus, 
the microarray systems that are now popular in research venues have not yet impacted significantly 
routine clinical settings [60]. 
To overcome these limitations with respect to time course, sampling and cost, recent advancements 
in the integration of bead sensors into microfluidic devices have demonstrated short timeframes for 
analysis that brings promise for their use at the point-of-care [61,62]. These highly sensitive sensing 
elements have attracted significant interest for the detection of biological and chemical agents for 
applications ranging from cardiac and cancer health, drug screening, and environmental screening [63–66]. 
Compared to the gold standard, enzyme linked immunosorbent assay (ELISA), which takes 2 to 24 h 
to complete, analyses with bead sensors can be completed in less than an hour [64,67]. Further, the 
multi-functionality of these beads introduced many possibilities for their incorporation into 
microfluidic devices for the detection of a wide range of analytes. Low nonspecific binding properties, 
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highly parallelized processes for production, and multiplexing capabilities of beads offer significant 
new opportunities for use in the context of near-patient testing.  
This review article examines the convergence of LOC technologies with bead-based sensor 
ensembles with biomarker validation alongside the use of porous media, so as to service the  
high-fidelity capture and analysis of a plurality of key biomarker systems in validated studies. While 
several prior reports have summarized the advantages of solid-state bead supports [61,67–69], the use 
of porous beads has not been covered previously in great detail. As summarized here, the enhanced 
mass transport, tunable porosities and high binding capacities of porous beads serve as key variables 
that have strong potential to lead to transformative changes in high-performance biomarker detection 
using scalable detection approaches. The combination of these elements allows for the development 
and deployment of high-performance platform systems that can function for the first time at the POC 
with performance that rivals the traditional remote laboratory instrumentation. 
2. Solid-State Bead Sensors  
2.1. High Surface-To-Volume Ratio  
Many modern bioscience analyte detection approaches such as ELISA utilize flat surfaces to 
generate signals. These approaches are limited by the low intrinsic signaling capabilities and slow 
transport characteristics afforded by these low-dimensional systems, which in most cases also rely on 
time-consuming amplification strategies. When compared to flat surfaces, 3-dimensional spherical 
beads offer significantly higher surface areas for immobilization of capture probes. For example, 
calculations by Kawaguchi show that 1 g of microspheres with a diameter of 0.1 µm has a surface area 
of 60 m2 [67]. With the same mass, further decreases in bead size would increase total surface area. 
Flat surfaces, however, are constant and limited to the open surface area available on the device. In 
contrast to the performance of flat surface-based immunoassays, the higher available surface area on 
beads increases sensitivities and lowers limits of detection [70]. 
When beads are interfaced with microfluidics, convective flow replenishes the analytes that become 
bound to capture probes. In contrast, assays performed with ELISA are for the most part static aside 
from some modest agitation where the dominant method for transport is diffusion. Because the 
diffusion distance is a few millimeters and the time to diffuse a distance is proportional to the square of 
the specific distance, ELISAs typically require several hours to overnight to perform [42]. The high 
surface-to-volume ratio of beads allows for timeframes of bead-based assays to be compressed relative 
to these planar counterparts. 
When microfluidics is integrated with bead-based capture ensembles, immunoassays can be 
performed over much shorter timeframes. For example, Sato et al. revealed the surface-to-volume ratio 
of 45 µm polystyrene beads was ~37 times higher than that of the flat surface in a microtiter plate [71]. 
Because of the high surface-to-volume ratios and the short diffusion distances afforded by the trapping 
of beads at the end of a barrier, the equilibration time for the capture of human secretory 
immunoglobulin A on beads was found to be 90 times less than that on flat surfaces. Likewise, the 
total analysis time was reduced from 24 h to less than 1 h. Similarly, Zammatteo et al. compared the 
capture of DNA probes on the surfaces of polystyrene microwells and beads [72]. When the total 
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surface area on the wells was equal to that on beads (1.4 cm2), the final signal was found to be similar. 
However, the incorporation of higher amounts of beads increased the total surface area for capture. In 
contrast, the total surface area for binding on microwells remained constant. By increasing the amount of 
beads per test by a factor of 4, the signals on microbeads were two times more than those of microwells. 
Moreover, nucleic acid hybridization kinetics performed much faster on beads than on microwells. 
2.2. Plug and Play 
Further, beads exhibit a high degree of practicality with respect to their production and 
incorporation into microfluidic devices. The synthesis of beads can be completed in a very scalable 
manner. Beads can be produced in bulk quantities on the order of millions to billions of beads per 
batch. Once made, the surfaces (and interior regions in the case of porous media) of such beads allow 
for the functionalization of a variety of a capture probes for both genomic and proteomic applications. 
The beads produced and functionalized in these batches exhibit high reproducibility for both size and 
chemistry considerations. Moreover, beads produced in such large numbers benefit from the 
economics of scale with lower cost associated to each sensor. Once processed, these beads can be 
stored for long durations (i.e., several years) until they are ready for use [7]. Multiple sets of beads 
functionalized with different capture probes can be quickly inserted into microfluidic devices as “plug 
and play” elements to address different clinical needs.  
In contrast, functionalization of capture probes on a planar microarrays is done through a very 
serialized, tedious, and time-consuming process [69]. For example, passive immobilization of 
antibodies usually requires several hours due to the slow rate of diffusion of free probes. During the 
attachment of capture probes, further quality assurance measures must take place to ensure the same 
immobilization conditions on surfaces treated with the same chemistry. Because beads are 
functionalized in batches, the statistical difference from bead-to-bead is very low. Further, a 
modification of an array necessitates the creation of new devices and a microarray configuration. With 
beads, a modification of a test panel is often as simple and an addition, subtraction, or replacement of a 
bead with different functionalized probes [70,73]. Functionalized beads can be inserted into chip 
structures within seconds using “pick and place” strategies adapted from the microelectronics industry. 
The ability to complete quality control on a large batch of beads in a highly parallel manner once, 
instead of completing similar oversight for every device that is generated by alternative spotting or 
lithographic reagent deposition steps, serves as a huge potential advantage for the bead sensor 
ensemble approaches and provides testament for the growing interests and popularity of the  
bead-based approaches in the bioscience and clinical measurement fields [7,74,75]. 
2.3. High-Throughput 
Often in clinical tests, the amount of sample is limited, such as is the case with neonatal testing. 
Further, prospective clinical trials and animal studies serve as additional areas where the completion of 
testing with minimal sample volume is critically important. Therefore, the ability to test for multiple 
analytes in a single sample simultaneously allows for efficient and faster results with the use of less 
expensive reagents and limited sample volumes. Microarray techniques have allowed for  
high-throughput testing in this capacity. Through the spotting of different capture probes on planar 
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surfaces, multiple analytes can be detected simultaneously as mentioned above. Each location is 
spatially encoded to detect a specific type of target analyte. Spatially recognizable software can decode 
and quantify each test location. Delehanty et al. used a microarray printer to spot antibodies on discrete 
locations within 6 channels of a glass slide. This development led to the simultaneous detection of both 
protein and bacterial analytes [76]. 
Similarly, bead sensors can be incorporated in large quantities into microfluidic devices to allow for 
highly parallelized detection of analytes and samples. The use of multiple beads to target a specific 
type of analyte permits statistical redundancy for high quality analyses. The multiplexing of beads 
functionalized with different capture probes can similarly be performed with minimal work [77,78]. 
For example, Ng et al. revealed that the incorporation of an array of polymer beads held by 
micropillars allows for the spatially addressable, rapid detection of nucleotides and multiple bacterial 
species [79]. This methodology afforded the capacity for DNA-based detection of 10 bacterial species 
and 2 single nucleotide polymorphisms in less than 10min. In addition, Zhao et al. used encoded 
photonic beads to simultaneously profile the biomarkers CA125, CA19-9, AFP, and CEA associated 
with tumors including colorectal, gastric, and lung cancer [80]. The use of silica colloidal crystal beads 
allowed for the identification of the four different bead types. Furthermore, the Walt group uses 3 µm, 
spectrally encoded polymer beads for detection of numerous targets [81–83]. This high-throughput 
platform can detect around 100 different DNA targets simultaneously with highly statistical precision 
through high redundancy of each bead types. 
Additionally, in the remote laboratory setting the integration of beads with suspension array 
technology (SAT) allows for rapid sample processing with rates in the thousands of measurements per 
second [84]. This platform decodes and measures encoded beads, typically only a few microns in 
diameter, in a flow cytometer. The combination of microbeads and flow cytometry technology can 
process through a 100-plex assay every 30 s [85]. Under a continuous automated process, this system 
can analyze almost 300,000 assays each day. Further, Kuckuck et al. demonstrated that the rate of 
processing can be further increased to 96-well plates per minute [86]. Here, the throughput limit 
approached the rate of the autosampler. SATs have evolved to accept beads for both applications in 
proteomics and genomics [87]. For example, SATs have allowed the high-throughput testing of 
pathogenic diseases [88], cytokines [89], and nucleic acid [90]. 
2.4. Encoding 
In multiplexed assays in planar microarrays, the identities of capture probes are determined from 
their positions in the array. This positional encoding affords microarrays the ability to perform 
thousands of tests simultaneously. Similarly, methods to attach a code to each bead (encode) allows for 
its differentiation (decode) from other bead types and permits parallel screening of multiple analytes in 
a single sample. 
One of the most common methods to encode beads is to employ a fluorophore. These luminescent 
dyes with different spectral characteristics and concentration values allow for a set of uniquely 
distinguishable codes. These spectrally encoded beads are commonly used in flow cytometers. 
Luminex Corp, one of most well-established bead-based instrument suppliers, uses three fluorophores 
to encode a panel of up to 500 different 5.5 µm beads. Each bead type is matched to a specific capture 
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probe. Using a 2-laser system, beads delivered through a suspension array are quickly decoded and 
their intensities are measured [91]. Similarly, BD Biosciences offers fluorescently dyed 7.5 µm beads 
of different concentrations [55,65,68,92]. With a two-laser system, these beads are analyzed inside the BD 
FACSArray which has multiplexed capabilities to detect up to four different spectral wavelengths [55].  
A 96-well plate containing processed samples can be analyzed at a rate of 15,000 events per second. 
The use of these spectrally encoded beads on these flow cytometry-based platforms have been 
demonstrated for the detection of single nucleotide polymorphisms [93], cytokines [94–96], bacterial 
pathogens [97,98], and infectious diseases [99]. Several studies, performed on these systems, reported 
analyses times much shorter than that of ELISA with sensitivities and increased dynamic ranges that 
compare or rival ELISA [85,100,101]. 
Similarly, Illumina developed a high-density optical fiber microwell array [81,102–104]. The tips of 
these glass optical fibers are etched with hydrofluoric acid to create a 5 µm well. When bundled 
together, this array contains 50,000 fibers with a diameter of 1–2 mm [102]. When immersed in a 
solution of spectrally encoded beads, tens of thousands of 3 µm beads randomly disperse and assemble 
onto the etched microwell array. After excess solution and microspheres are removed, an imaging 
system decodes and quantifies the signal on each bead. The microarray has a test density that is 
significantly higher than that on an automatically spotted planar microarray. Because of this high 
density, only a small volume of sample is required to run tens of thousands of tests in a single run. 
Similarly, Illumina has also developed an etched silicon chip containing a hexagonal array of 
microwells, each measuring ~3 µm, that can hold randomly dispersed beads. Using a CCD camera, 
individual beads are decoded and quantified. BioArray Solutions, which was purchased by Immucor, Inc. 
in 2008, uses a similar technology as Illumina. In this BeadChip format, encoded beads are randomly 
patterned onto a silicon chip, for the detection of complex nucleic acids and proteins [105,106]. Figure 1 
showcases some of the current nonporous bead-based clinical analyzers that are used for remote 
laboratory measurements. 
Figure 1. Current solid-state bead-based clinical laboratory analyzers include the  
(A) Luminex 100/200, (B) BD FACSArray, (C) Diasorin Liaison, and (D) Illumina 
BeadXpress.  
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One limitation of these encoding schemes is the complication of possible overlap between spectral 
encoders or reporters. This complication limits the potential amount of simultaneous tests that can be 
performed in a single assay to about 100 different groups. The positionally-addressable identification 
of bead types, analogous to location-based encoding in microarrays, may extend the limit of different 
tests performed in a single assay. For example, Ng et al. used an array of polyacrylamide gel pads to 
form pillars to trap different bead types. Because of the natural immobilization of beads to the 
polymeric matrix, beads with similar probes are easily anchored in gaps between the micropillars. A 
second set of beads with a different probe set, spotted onto different positions of the array, allow for 
the differentiation of bead types. This process can be repeated to attach different beads [79,107]. 
Similarly, the Ikami et al. immobilized microbeads in hydrogel supports to allow for position-based, 
addressable decoding [108]. Here, fluid containing microbeads with similar capture probes is  
photo-polymerized with a photomask to form a hydrogel pillar. Uncured solution is washed. The 
process is repeated for beads with different probe sets. This bead-hydrogel device allows for the 
simultaneous detection of three proteins in about 4 min using only 0.5 µL of total sample and reagents. 
Other less common approaches to encode beads include chemical, graphical, electronic, and physical 
encoding [69]. 
3. Towards Point-of-Care 
The advantages of high-throughput multiplex testing through high surface-to-volume ratios of solid 
support beads have allowed for shorter analysis times with low sample and reagent requirements. 
Nonetheless, the timeframes to complete these tests are often still not consistent with the POC [109,110]. 
For example, a typical doctor’s visit that lasts 15–30 min does not permit for a diagnostic test that 
requires more than 1hr to complete. Previously, a set of guidelines for POC tests has been developed 
and designated with the acronym COMMAND QUALS [75]. Likewise, clinical analyzers need to be 
Cheap, Obvious, Miniaturized, Multiplexed, Automated, Nonperishable, Dependable, Quick, 
Unobtusive, Adaptable, Limited (volume), and Self-contained.  
Improvements in mass transport and high-efficiency signaling are crucial here to achieve the ideal 
timeframes and high-fidelity analyte detection using simple instrumentation as is necessary in POC 
usage. Advantages of enhanced mass transport in porous mediums, such as gel pads and hydrogels, 
have demonstrated faster timeframes over planar microarrays. With the ability to functionalize a range 
of different capture probes, these porous networks have the ability to capture a wide range of analytes. 
The development of new microstructure concepts with engineered active transport through and within 
porous reactive particles serves as a promising new method for rapid yet high-efficiency capture within 
minisensor ensembles [111–114]. The ability for analytes to transport into the interior matrix and high 
capacities for capture probes have allowed for shorter analysis times and higher sensitivities than those 
of planar microarrays [115,116]. 
In the supported porous bead array area, prior efforts have led to the development of a microfluidic 
bead-based platform termed the Programmable Bio-Nano-Chip (p-BNC). This p-BNC platform is 
based on the concept that multiplex assays for a variety of disease applications could be achieved on a 
modular sensor suite that combines an application specific cartridge in conjunction with a universal 
analyzer. The approach uses a sensing platform that employs an array of 280 µm porous, agarose beads 
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4. Porous Bead Sensors 
In contrast to a 2-dimensional planar surface of a typical microfluidic structure, high surface-to-volume 
ratios of porous substrates allow for enhanced sensitivities and lowers limit of detection values for 
delivered analytes [71,119]. Due to the sizes of biomolecule capture agents such as antibodies and 
limited surface area for immobilization, the capacity of binding on flat surfaces is significantly less 
than that for porous media [74]. The kinetics of binding of analytes to probes in highly porous media is 
often described as near-solution kinetics [68]. Here, reaction kinetics between a molecular analyte and 
an immobilized molecular capture probes occur as rates similar to those of two free molecules in 
solution. Further, internal transport and high binding densities characteristic of sporous substrates 
make these sensors suitable alternatives to current detection technologies, where rapid results are 
desirable for low volumes of sample containing low concentrations of target analyte. 
Likewise, the p-BNC method that utilizes the porous bead as an immunosensor meets and often 
exceeds analytical characteristics, such as test dynamic range and limit of detection [7] of mature 
research or commercial instrumentation for a wide variety of analyte systems, thereby allowing 
dilution of the sample, if needed [24,28]. 
The strong analytical performance of the p-BNCs can be linked directly to the porosity and  
3-dimensionality of the agarose bead capture elements. The choice of agarose is based in part on the 
potential for scalability, as it is derived from inexpensive sources (i.e., seaweed). The same beads are 
already made in large quantities to support immunochromatographic applications that are dedicated to 
applications such as the purification of proteins. In addition to its tunable porosities (see below), this 
polymerized sugar matrix exhibits ultra-low nonspecific binding characteristics and the medium is 
index matched with water. The latter optical characteristics (unlike paper) make the material ideal not 
only for separation, but also as an environment (i.e., a mini-cuvette) for optical detection. 
Other advantages of the agarose bead sensors include (a) a capacity to be tailored so as to 
accommodate the specifications (such as molecular weight, size and shape) of the targeted analytes,  
(b) a capacity to be implemented for both two-site immunometric as well as competitive assays, (c) a 
capacity to be mass produced for widespread clinical purposes, (d) a capacity to be stabilized so as to 
withstand extreme storage conditions, (e) similar to immunochromagraphic applications, a capacity  
to be recycled for successive assay runs, as needed, and (f) a capacity to support fluorescence-, 
colorimetry-, and electrochemistry- based signal transduction [120]. 
4.1. Fibrous Network 
Agarose beads are typically produced in bulk using standard emulsion polymerization methods [121]. 
By varying the agitation conditions, the gel temperature, the surfactant concentration and the feedstock 
concentrations, it is possible to obtain agarose beads of sizes ranging from 15 µm to more than 500 µm. 
Further, judicious choice of conditions can be used to isolate beads with agarose weight concentration 
values that vary from 0.5% to 8%. Important to note is the fact that the balance of the bead is 
composed of the background solvent and as such this medium serves as an ideal bridge between the 
solution and the solid-state support. Beads of specific diameter are further selected using sieving 
methods, as previous described [111]. Importantly, the control of agarose content by weight during the 
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efficiency is 23.5% at a 400 µL/min flow rate with 4% agarose bead. To secure the same 23.5% level 
of capture with planar microarrays, it is necessary to slow down the flow rate and wait at least  
3× longer. This extension in timeframe places some restrictions on the prospects for near-patient 
testing for planar microsystems that lack alternative capture methodologies. 
4.2. Fibrous Network 
The hydrophilic fibers within the porous medium allow for the functionalization of a variety of 
capture probes. For example, several groups have successfully demonstrated the functionalization of 
hydrogel for the detection of a range of analytes that include proteins, nucleotides, and cells [124–126]. 
Moreover, the hydrophilic surfaces of these fibers retain better protein activity over that of planar 
surfaces [127]. Scanning electron microscopy (Figure 6(A)) shows the surface morphology of a 
porous, homogenous bead created using an emulsion method [111]. While at first glance, the surface 
appears smooth, at higher magnification, as shown in Figure 6(C), details of the fibrous network are 
revealed. The densely packed nanofibers here exhibit pore sizes of approximately 100–200 nm in 
diameter. This range agrees with microscopy measurements within non-spherical, porous  
medium [128,129]. Figure 6(B) shows the surface morphology of a superporous bead. These beads, 
produced through double emulsion, exhibit large macropores that form interconnected tunnels within 
the bead. Magnification of the non-cavity regions show similar pore sizes as the homogenous case, as 
shown in Figure 6(D). Furthermore, because of the 3-dimensional geometry of a bead, the signals 
acquired from the bead are typically aggregations of thousands of layers. For example, signal on a 
bead is derived from a thickness that is 1,000–20,000 times larger than that from a flat monolayer on a 
ELISA plate [74]. 
Figure 6. SEM images comparing porous agarose beads. (A) SEM images showing the 
surface morphology of homogenous beads containing 4% agarose and (B) superporous 
beads containing 4% agarose with ~30 µm microcavities that allow for rapid access of 
fluids in the interior matrix of the bead. (C) Corresponding SEM images of fibrous 
networks for homogenous bead and (D) superporous bead. 
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Transport into the bead matrix is dependent on external flow rate and the pore size of the dense 
fibrous matrix [130]. Careful tuning of the pore size allows for control of the mass transport within 
porous beads. Thompson et al. developed a model in an attempt to understand the effects of analyte 
diffusion coefficient, flow rate, and capture probe density on the kinetics on bead surfaces [131]. Further, 
the combination of confocal microscopy and computational simulations helped to define the spatial and 
temporal distribution of bound biotinylated quantum dots on streptavidin-coated beads [132]. 
Prior work here has revealed the existence of internal convection within porous beads. The unique 
design employed by the p-BNC, consisting of individual beads in flow-through microcontainers, 
allows for pressure-driven convective transport of analytes within the porous matrix [117]. This 
pressure-driven design, which forces fluids into the porous medium, increases analyte-antibody 
interactions and allows for faster signal generation. When porous beads are employed in lateral flow 
designs, however, the convective transport within the bead matrix is limited [133,134]. Instead, the 
poor capture efficiency between antibody and antigen results in equilibrium saturation times of several 
hours [116,134]. To overcome such limitations, Bau et al. implemented a breathing bead methodology 
to expand and compress porous beads to accelerate mass transfer within such beads to increase signal 
intensity by a factor of ~2.5 [135]. Within the p-BNC, the use of an intimate contact between the bead 
ensemble and the porous beads appears to be essential to create a pressure gradient atop the bead that 
can be used to facilitate the internal transport within the bead interior [136]. 
Further, modification of the pore size through control of agarose content in the beads allows for the 
increase of internal transport. In contrast to lateral flow designs, the flow-through design redirects 
fluids to create a high-pressure gradient that enhances internal mass transport. An adaptation of the 
Koreny-Carman equation shows that fluid velocity in a porous medium is proportional to applied 
pressure gradient and square of the pore diameter [137]. Previous studies have revealed that the 
internal convective transport is linearly proportional to the rate of bulk fluid delivery [138]. When the 
agarose concentration of the bead is increased from 0.5% to 8%, the ratio of the internal to external 
flow rates decreases from 1:170 to 1:3,100, equivalent to an 18-fold decrease in internal convective 
transport [117]. 
Superporous beads have shown promise to enhance the mass transport of analytes that include 
proteins and cells into the internal bead matrix [139–142]. In addition to the fibrous network with pore 
sizes between 100–800 nm, as in the case of homogenous beads, superporous beads also contain large 
flow cavities with diameters of 10–30 µm [74]. These cavities of micropores allow for quicker access 
of fluids into the bead core and reduce equilibrium times than those exhibited by homogenous beads 
with similar sizes of micropore. For example, Larsson et al. observed intra-particle fluid velocities in 
superporous beads to be as high as 17% of the interstitial velocity in a chromatography column [130]. 
Moreover, the use of superporous beads have been shown to reduce back pressure build-up in 
microfluidic devices [143]. Large cavities with diameters of 30 µm result in craters on the surface. 
Internally, these craters lead to interconnecting cavities that form long tunnels for easy access of fluids 
into the interior matrix (Figure 7(B)). 
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As revealed by simulations, Figure 8 compares the spatial distribution of bound analytes within 
porous beads under low (0.04 mg/mL), medium (0.12 mg/mL), and high (2.5 mg/mL) binding 
densities of anti-BSA capture probes at 30 min and 120 min of analyte delivery. At high densities of 
capture probes, mass transport of free analytes to the internal core of the bead matrix is limited  
(Figure 8, bottom). Here, the short residence time of the free analyte results in high signal localized at 
the rim of the bead. However, as initial capture probes at the rim of the bead become bound, a moving 
boundary of bound analytes develops and penetrates radially towards the center of the bead matrix. 
This moving boundary continues as free analytes bind to internal capture probe sites, until the bead is 
completely saturated with bound analytes. In contrast, lower capture probe densities result in lower 
saturation intensities, but allow for faster analyte binding into the bead matrix (Figure 8, top). Here, the 
moving boundary permeates radially towards the center of the bead at a much faster rate than that for 
high capture probe densities. As shown in Figure 8, under the same timeframes, the uniform 
distribution of signal develops under 0.04 mg/mL of capture antibodies while a higher signal is 
localized at the rim of the bead under 2.5 mg/mL of capture antibodies. Because the percentage of 
available capture probes decrease at fast rate, signal quickly reaches equilibrium at the rim of the bead 
and then within the internal matrix of the bead. These results derived by simulation have also been 
validated through experimental studies [117]. 
Figure 8. Spatial distribution of fluorescently-labeled BSA, as a function of microbead 
receptor concentration and time, as predicted by finite element analysis, at the diametral 
plane of the microbead under different binding densities. 
 
Furthermore, the density of binding is nonlinear to the concentration of capturing antibody used for 
conjugation. While porous medium offers high capacities for binding, no further benefits in signal 
occurs as higher concentrations of probes are used for immobilization due to saturation of available 
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sites for antibody immobilization. For example, the high, medium, low densities of capture probes 
shown in Figure 8, corresponding to a capture probe density of 100:4.8:1.6 ratio, result in a respective 
intensity ratio of 100:59:13. For superporous beads, Yang et al. witnessed limited signal increases for 
capturing antibody concentrations higher than 0.5 mg/mL [143]. While there exists a critical antibody 
density that does not allow for further binding, the capability for binding resulting from the high 
surface-to-volume ratio in the bead matrix exceeds that of planar surfaces and allows for higher 
sensitivities. While the total surface area for binding is limited, an increase in agarose content during 
the production of the beads, or higher agarose concentration, allows for more surface area for binding. 
As such, the interplay between porosity and capture probe concentration allows for control of bead 
sensitivities as well as assay response times. 
5. Steps toward Broad-Scale Clinical Practice 
Having clearly articulated the analytical performance advantages of using porous beads for 
biomarker capture with microstructures, it is now essential to explore the next critical steps required to 
use these mini-sensor ensembles in real-world clinical practice. Indeed, despite large investments in 
translational research programs, most bioscience research efforts remain largely decoupled from 
broad-scale clinical practice, both for the biomarkers as well as for the devices that measure them [7]. 
This general trend extends to medical microdevices and LOC systems as has been highlighted in recent 
perspective articles [54,145]. The typical structure associated with the device development process, 
whether from academia, national labs or the industrial sector, is a succession of lengthy steps that often 
happen in a linear, sub-optimal and disjointed manner taking considerable time and draining precious 
resources and momentum out of venture capital and federal funding, alike. 
A case in point for the dismal rate of translation of new medical tests into real-world practice is 
extracted from a recent analysis by Schully et al. [146] of the Fiscal Year 2007 extramural grant 
portfolio of the National Cancer Institute (NCI), as well as cancer genetic research articles published in 
2007. The group classified both funded grants and publications as follows: T0, as discovery research; 
T1, as research to develop a candidate health application (e.g., device or therapy); T2 as research that 
evaluates a candidate application and develops evidence-based recommendations; T3 as research that 
assesses how to integrate an evidence-based recommendation into cancer care and prevention; and T4 
as research that assesses health outcomes and population impact. They found that 1.8% of the grant 
portfolio and 0.6% of the published literature was T2 research or beyond.  
In an attempt to move the medical microdevices and porous bead sensor systems into broad-scale 
clinical practice, a number of clinical trials and pilot studies have been initiated. Likewise, the 
laboratory version of the p-BNC bead-based methodology described above along with a related 
membrane-based system not covered here are now involved in six clinical trials and two pilot studies, 
respectively, involving over 5,000 patients, including over 10 clinical sites for diseases in the areas of 
cardiac heart disease, ovarian cancer, prostate cancer and drugs of abuse (See Table 1) [147–149]. 
High-impact diseases and conditions, such as cardiovascular disease and various cancers, including 
ovarian cancer and prostate cancer are the targets of these p-BNC development and biomarker 
validation trials. The ability to use validated biomarkers in a common platform affords interesting 
synergies with respect to opening up new and more efficient treatment methods for management of 
Sensors 2012, 12 15485 
 
 
patients [7,8]. The same platform approach is also dedicated to testing for anti-epilepsy drugs, as well 
as drugs of abuse, with targeted applicability in various settings, including home and the identification 
of drivers under the influence of drugs, at the point of arrest.  
Table 1. The bead-based p-BNC is involved in six clinical trials through several major 
sponsors to target a number of diseases though the validation of a number of biomarkers.  
Study Sponsor Area 
# Of 
Subjects 
Clinical Site Biomarkers
Development of A  
Lab-on-a-Chip System 
for Saliva-Based 
Diagnostics 
National Institute of 
Dental and 
Craniofacial 
Research 
(NIDCR) 
Cardiac 
Disease 
1,050 
patients 
Baylor College 
of Medicine 
15 proteins 
Advanced Bio-Nano-
Chips for Saliva-Based 
Drug Tests at the Point of 
Arrest 
Home Office-Center 
of Applied Science 
and Technology 
(HO-CAST) 
Drugs of 
Abuse 
340 
participants 
Baylor College 
of Medicine 
12 drugs 
Texas Cancer Diagnostics 
Pipeline Consortium 
Cancer Prevention 
Research Institute of 
Texas 
(CPRIT) 
Ovarian 
Cancer 
2,660 
patients 
MD Anderson 
Cancer Clinic 
4 proteins 
Cancer Prevention 
Research Institute of 
Texas 
(CPRIT) 
Prostate 
Cancer 
1,100 
patients 
UT Health 
Science 
Center-San 
Antonio 
3 proteins 
Pilot and Prospective 
Studies for the 
Development of the 
Trauma Chip 
Texas Emerging 
Technology Fund 
Acute 
Kidney 
Failure 
120 patients 
UT Health 
Science 
Center-
Houston 
5 proteins 
Development of p-BNCs 
for the Monitoring of  
Anti-Epilepsy Drugs 
Levels in Saliva 
John S. Dunn 
Foundation 
Epilepsy 100 patients 
UT Health 
Science 
Center-
Houston 
3 proteins 
The capacity of the p-BNCs to multiplex, or simultaneously measure multiple analytes within a 
single assay run, is not only economically beneficial, but it also allows to test for biomarkers that 
collectively provide a more comprehensive look into the overall well-being of a person, while at the 
same time derive a more specific look to specific stages of the disease process. 
Case in point, to date there are no global methods to define in an efficient way the entire 
cardiovascular health of patients. Today cardiac heart disease is the number one killer globally [150]. 
While there are many good approved biomarkers, it has not been cost effective to manage patient’s 
care through measurement of all of these biomarkers for all patients [150]. Cost restrictions and a lack 
of understanding of the disease progression have limited progress in this area. With these limitations in 
mind, recent efforts target the development of customized cardiac chips that could evaluate the overall 
cardiovascular health of patients.  
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For example, biomarkers for all aspects of care regarding cardiovascular disease, including 
diagnosis of acute myocardial infarction, prognosis or risk for secondary cardiac events, monitoring, 
risk stratification and guidance for therapeutic interventions of cardiac patients, were developed as 
multiplexed panels [150]. Figure 9 details the use of porous agarose beads, as supported in the p-BNC 
in this capacity. Here, four panels of multiplex biomarkers target different cardiovascular diseases that 
include the risk for primary cardiac event, expanded acute myocardial infarction (AMI) diagnosis, risk 
for secondary cardiac events, and congestive heart failure. Panel sizes and bead sensors are easily 
swapped to serve the needs of the diagnostic application. Noted for each array is the redundancy of 
bead sensors per analyte, which contributes to accurate and precise measurements. Also, noted here is 
the presence of calibrator beads (Cal), which serve for the baseline calibration of the p-BNC system, 
and negative control (-ve CTL) beads, coupled to antibodies irrelevant to any of the analytes targeted 
in each test, which serve as indicators of the specificity of the antigen-antibody reactions that take 
place within the lab card. 
Figure 9. The p-BNC diagnostic applications for cardiovascular disease include (A) Risk 
for primary cardiac event chip: Apolipoprotein A1 (ApoA1), Apolipoprotein B (ApoB),  
C-reactive protein (CRP), Interleukin-1beta (IL-1b), Monocyte chemoattractant protein-1 
(MCP-1), Tumor necrosis factor-alpha (TNF-a), Soluble CD40 ligand (sCD40L), Human 
serum albumin (hsa), Interleukin-6 (IL-6) and Myeloperoxidase (MPO); (B) Expanded 
AMI diagnosis chip: Cardiac troponin I (cTnI), Myoglobin (CRP), IL-1β, MPO and MYO; 
(C) Risk for secondary cardiac events chip: ApoA1, ApoB and D-dimer; and (D) 
Congestive heart failure chip: Brain natriuretic peptide (BNP)  
 
Key to future successful implementation of these tests is the fact that they meet the analytical 
performance requirements, as dictated by the pathophysiological levels of the various biomarkers for 
healthy vs. diseased. Likewise, in order for these chip-based tests to have clinical relevance, they must 
not only respond on a timeframe consistent with near-patient usage, but they must meet or exceed the 
analytical, and, thereby, clinical performance of the gold standards or reference methods, that are for 
the most part limited to the laboratory setting (see Table 2). With this in mind, a significant amount of 
effort has now been devoted to the determination of the analytical performance of key biomarkers 
using the porous bead sensor systems. These measurements are completed using human clinical 
samples and thus move above and beyond the common starting place of purified antigens within  
buffer solutions. 
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Table 2. Initial specifications obtained with laboratory-based p-BNC porous bead-based 
approach: List of developed biomarker assays, targeted use, and device performance 
characteristics in the context of real-world clinical testing. 
Biomarker Clinical Use Range a (ng/mL) LOD a (ng/mL) Method 
C-reactive protein AMI, Risk Assessment 0.1–10,000 0.1 Theoretical
Soluble CD40 ligand Cardiac Risk Assessment 0.1–1,000 0.1 Practical 
Monocyte chemoattractant protein-1 Cardiac Risk Assessment 0.001–20 0.001 Practical 
Myeloperoxidase Cardiac Risk Assessment 0.05–500 0.05 Practical 
Myeloperoxidase (multiplexed) Cardiac Risk Assessment 1.2–500 1.2 Theoretical
Interleukin-1beta Cardiac Risk Assessment 0.001–1 0.001 Practical 
Interleukin-6 Cardiac Risk Assessment 0.001–1 0.001 Practical 
Tumor necrosis factor-alpha Cardiac Risk Assessment 0.01–10 0.01 Practical 
Cardiac troponin I AMI Diagnosis 0.05–50 0.05 Theoretical
Myoglobin AMI Diagnosis 0.1–1,000 0.1 Theoretical
CK-MB AMI Diagnosis 1.7–50 1.7 Theoretical
Apolipoprotein A1 Risk for recurrence/Prognosis 1–1,000 1 Practical 
Apolipoprotein B Risk for recurrence/Prognosis 1–1,000 1 Practical 
Brain natriuretic peptide Congestive Heart Failure 0.05–10 0.05 Theoretical
N-Terminal proBNP Congestive Heart Failure 0.1–500 0.1 Theoretical
Human serum albumin Cardiac Risk Assessment 1–1,000 1 Practical 
Transferrin Blood contamination in saliva 0.05–10,000 b 0.05 b Theoretical
Carcinoembryonic antigen Ovarian Cancer 0.1–100 0.02 Theoretical
Cancer antigen 125 Ovarian Cancer 1–400 c 1 c Theoretical
Human ep growth fact Rec. 2-neu Ovarian Cancer 0–60 0.27 Theoretical
Prostate-specific antigen Prostate Cancer 0.1–100 0.1 Theoretical
Free prostate-specific antigen Prostate Cancer 0.1–100 0.1 Theoretical
Complexed prostate-specific antigen Prostate Cancer 0.63–100 0.63 Theoretical
Cocaine Road Side Drug Testing 1.3–10,000 1.3 Practical 
Diazepam Road Side Drug Testing 0.14–1,000 0.14 Practical 
Tetrahydrocannabinol Road Side Drug Testing 0.22–10,000 0.22 Practical 
D-Amphetamine Road Side Drug Testing 0.22–1,000 0.22 Practical 
Methamphetamine Road Side Drug Testing 10–8,000 1 Practical 
Oxazepam Road Side Drug Testing 1.6–100,000 1.6 Theoretical
Nordiazepam Road Side Drug Testing 0.72–100,000 0.72 Theoretical
Temazepam Road Side Drug Testing 1.1–100,000 1.1 Theoretical
Morphine Road Side Drug Testing 0.46–1,000 0.46 Theoretical
Methadone Road Side Drug Testing 1.02–10,000 1.02 Theoretical
MDA Road Side Drug Testing 7.1–1,000 7.1 Theoretical
MDMA Road Side Drug Testing 0.41–1,000 0.41 Theoretical
a all units are ng/mL unless otherwise specified. b units are expressed here as µg/mL. c units are expressed 
here as U/mL. 
With this real-world clinical context in mind, the limits of detection (LODs) for the two-site 
immunometric and competitive assays have been established as reported in Table 2. Here both 
practical and theoretical methods for determination of LOD values have been employed [151–153]. 
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The former method was used for some of the initial work and the latter for the majority of the more 
recent activities. For the theoretical LOD values, a 4- or 5-parameter logistic curve fit was applied to 
the dose response curve and then the intersection with the intensity level three standard deviations 
above the zero calibrator mean of three trials was established to yield the concentration value that 
defines the LOD. In cases where no ultra-low concentration standards were run, the practical method 
was used. Here the LOD was established as the lowest concentration of antigen yielding an average 
bead signal that lies at three standard deviations above (two-type immunometric) or below 
(competitive) the mean value recorded for the zero analyte calibrator. 
From Table 2 it can be seen that the p-BNC tests for drugs of abuse exhibit exceptional assay 
performance characteristics with limits of detection (LODs) comparable to the laboratory-confined 
reference method of LC-MS/MS and vastly superior (significantly lower) than their 
immunochromatographic (ICS) counterpart tests. Similar to LC-MS/MS and unlike ICS tests, which 
are qualitative (Yes/No) type of tests, p-BNC-based drug tests are fully quantitative. Furthermore, 
unlike LC-MS/MS which requires tedious sample processing and is limited to testing for one drug at a 
time, p-BNC tests once in their final format, will be amenable to the point of need, require no 
extensive sample processing and offer the capacity to multiplex, or test more than one analyte (drug) 
concurrently, using microliters of sample.  
6. Current Bead-Based Analyzers 
Table 3 showcases current bead-based analyzers and the timeframes to complete the test. Given the 
timeframes to perform an analysis, most analyzers based on solid support bead sensors are confined to 
testing in the clinical laboratory. For example, the Luminex xMap system, which employs a suspension 
array technology to detect multiple analytes simultaneously, has a timeframe for detection that is in the 
range of two hours to overnight. It is apparent that the timeframes offered would not be ideal for  
point-of-care testing. As such, an increase in the sensitivity of bead-based approaches would lend to 
faster analysis times that are suitable for point-of-care testing. 
Table 3. List of bead-based instruments, number of different bead sensors for 
multiplexing, and total time to complete a test.  
Instrument  Source  Total Tests  Time  Setting  
xMap  Luminex  500  390 min  Laboratory  
BD FACSArray  BD  35  35 min  Laboratory  
AtheNA Multi-Lyte  Alere  26  60 min  Laboratory  
VeraCode BeadXpress  Illumina  48  30 min  Laboratory  
Liaison  Diasorin  144  60 min  Laboratory  
p-BNC *  McDevitt Lab  100  20 min  Lab & POC  
* The analyzer and biochips associated with the p-BNC approach for porous beads are still in development 
and are not yet commercially available. Specifications are being developed for future technology transfer 
through commercial partnerships. Characteristics listed in the table are projected for ultimate use. 
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The combination of porous support beads and tailored microstructures with active transport features 
allows for enhanced mass transport of analytes. Short analysis timeframes of these highly sensitive 
sensing elements reduce analysis times achieving what would be consistent with the point-of-care. 
7. Scalability 
As mentioned above, in order for the medical microdevices area to reach their full potential, it will 
be necessary for these mini-test ensembles and their associated measurement platforms to be fully 
validated with results that exhibit strong performance characteristics that rival those achieved in 
traditional laboratory settings [7]. Further, it will be necessary that these devices show scalability and 
performance that exceeds existing laboratory capabilities. To be scalable, enhanced performance must 
be achieved with reduced cost and increased efficiencies. 
The pathway to scalability would be expected to occur with modular assay formats that encompass 
major diagnostic classes and with the establishment of standard testing procedures [7]. It is in this 
capacity that the microelectronics industry should be considered to be a key model for the diagnostics 
industry to follow. While initial discoveries in the electronics area, such as the vacuum tube, offered 
basic logical operations, large mainframes and electrical component failures limited the widespread 
adoption. However, with the advent of the solid-state three-point transistor and photolithographic 
processing that brought standards and scalability, the microelectronics industry pushed the limits of its 
capabilities as components became smaller and more powerful. Furthermore, for this now dominant 
industry, Moore’s law serves as a goal to produce increased computational power at reduced cost. 
Unfortunately, today healthcare costs are increasing at an alarming rate with only modest increases 
in the quality of patient care [154]. Today over 60%–70% of medical decisions are made with 
consultation of clinical testing results, yet less than 5% of total costs in this space are associated with 
the testing results [155]. Likewise, it is clear that there is good value in clinical testing and information 
content here derived will play an important role for the future management of healthcare and wellness. 
It might be expected, therefore, that the development of scalable high-performance diagnostic 
platforms alongside Moore’s law-like goals could have potential to lead to transformative changes in 
healthcare. Figure 10 provides a representative list of diagnostic instruments and shows how the 
number of tests that are performed per session have evolved with time. In assembling this information, 
the “Q” quotient is used, as this value designates the number of tests that are performed per person per 
time [75]. With this quantity in mind, the focus is placed directly on the information content as needed 
to impact clinical decision making for the individual patient. In this capacity, the time value here 
designated includes transit, preparation, and analysis periods. From this graph, it is quite interesting to 
note that bead-based systems and chip-based approaches are now providing the highest level of 
information extraction to date. It is also interesting to note that, similar to the field of microelectronics, 
there is an evolving trend with time to secure more biomarker-derived information.  
For the purpose of this graph, it is assumed that all the information content obtained from 
microarray discovery data is used in the clinical decision making process. However, more typically 
only a small number of sequences contribute to the differential disease diagnosis and thus these 
specific signatures serve as a small portion of the acquired information. In the future it might be 
expected that as these devices move closer to widespread clinical practice, a stronger focus on key 
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information from the selected sequences derived from more efficient capture methods will evolve. 
Integrated LOC systems with improved efficiencies in sample processing are expected to play key 
roles in extracting the key information that is required to manage patient care in cost effective and 
efficient ways moving forward. 
Figure 10. Graph over time showing the increase in Q, the number of tests performed per 
person per time, for various representative diagnostic approaches. 
 
8. Conclusions 
In many ways, the convergence of microfluidics, biomarker validation, and porous bead ensembles 
serve to overcome some of the significant challenges that the medical microdevices have, to date, 
faced with respect to scalability and performance. When combined with new concepts for noninvasive 
sampling [156], there is now strong potential to move these sensor modalities into broad-scale clinical 
practice. Before this is possible, it will be necessary to complete more thorough clinical testing and 
validation. The ability to complete multiplexed testing on porous beads that can be customized for 
response time allows for multiple biomarkers to be measured within one environment in ways that 
would not readily be achieved with more traditional planar approaches. Further, the prospect for using 
the same diagnostic core in the discovery, clinical validation and broad-scale testing serves to establish 
a promising pathway that has potential to increase the pace of both new device and new biomarker 
approvals [7]. 
Further, the power of scalability through reduced time per test could lead the way to a new 
generation of diagnostic and detection tools for health care applications. These devices, with the ability 
to quickly provide robust, affordable, and accurate results, could potentially diagnose diseases at early 
stages, monitor health risks, manage illness and provide appropriate treatment options [37]. The ability 
to detect disease early on can improve the quality of the patient life, influence life style changes, and 
Sensors 2012, 12 15491 
 
 
reduce overall treatment costs. As such, these advanced medical microdevices may serve as the 
enabling technology base that can help to usher in long awaited transition from reactive to preventative 
medicine [54]. 
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